Reports

Cisco delivered strong performance in Q3 FY25, with $14.1B in revenue and $2.5B in net income. The company surpassed its AI infrastructure order target ahead of schedule, driven by growth across all geographic and product segments.

• Revenue for Q3 FY 2025 was $14.1 billion, an increase of 11% year over year, surpassing the high end of their guidance.
• GAAP EPS was $0.62 and Non-GAAP EPS was $0.96, both above the high end of their guidance range.

Sony delivered solid Q4 results with ¥197.7B in net income and ¥2.63T in revenue. While overall sales declined due to a sharp fall in financial services revenue, operating income remained healthy. The Music and Pictures segments were key contributors to growth.

• Revenue for Q4 was ¥2.63 trillion, down from ¥3.48 trillion the previous year
• Net income rose to ¥197.7 billion despite revenue decline

In Q1 2025, Telefónica achieved 1.3% organic revenue growth and maintained solid EBITDA performance. Net income from continuing operations was €427 million, while losses from divested units led to a total net loss. The company maintained a healthy liquidity position and confirmed its dividend plan.

• Organic revenue grew 1.3% YoY to €9.22 billion, driven by B2C and B2B segments.
• Net income from continuing operations reached €427 million.

STERIS delivered a 4% revenue increase in Q4 2025, supported by solid gains in service and consumables, though Life Sciences saw a decline due to divestiture impacts.

• Q4 revenue rose to $1.5 billion, up 4% year-over-year.
• Adjusted EPS increased to $2.74 from $2.41 a year ago.

Dynatrace delivered a strong finish to fiscal 2025, exceeding the high end of guidance across all FY25 metrics. The company achieved 17% total revenue growth and 18% subscription revenue growth in Q4, both on an as-reported basis, and reported strong profitability and free cash flow.

• Total ARR increased 15% year-over-year to $1,734 million.
• Total Revenue grew 17% year-over-year to $445 million.

In Q1 2025, YPF posted total revenues of 4608000000 with a net loss of 10000000, while adjusted EBITDA was reported at approximately 1245000000 and shale oil production increased materially compared to the year-ago period.

• Total revenues were 4608000000 for the quarter.
• Net loss was 10000000, significantly narrower year-over-year.

Revenue grew 21% YoY to $245.5M driven by robust travel demand across all segments, while adjusted EPS rose to $0.42. Net income declined sharply due to a prior-year tax gain, but operational metrics were strong.

• Revenue rose to $245.5 million, up from $202.9 million in Q4 FY24
• Adjusted net profit grew to $48.1 million from $36.9 million

Global-E delivered a robust Q1 2025 performance with a 30% year-over-year increase in revenue and a significant boost in GMV. Despite posting a net loss, the company improved its profitability metrics and strengthened its partnership with Shopify.

• Revenue grew to $189,882,000, driven by both service and fulfillment segments.
• Gross Merchandise Value increased by 34% YoY to $1,242,514,000.

Nextracker delivered a strong Q4 FY25 with record quarterly revenue of $924 million and net income of $158 million. The company launched a new eBOS business with the acquisition of Bentek and ended the year with strong cash reserves and no debt.

• Achieved record Q4 FY25 revenue of $924 million, up 26% YoY
• Reported GAAP net income of $158 million and EPS of $1.05

Boot Barn delivered robust Q4 results with 17% revenue growth and a 28% rise in net income, fueled by strong same store sales and margin improvements.

• Revenue rose 17% year-over-year to $453.7 million.
• Net income climbed to $37.5 million, a 28% increase from Q4 2024.

Tower Semiconductor achieved a 9% year-over-year revenue growth in Q1 2025, while maintaining gross profit levels. Net income decreased due to a prior year tax benefit, but operational performance remained consistent.

• Revenue rose to $358,170,000, up from $327,238,000 in Q1 2024.
• Net income declined to $40,142,000 due to a non-recurring tax benefit last year.

Cellebrite saw solid revenue growth driven by a 21% increase in subscription revenue, alongside improved profitability and strong ARR momentum.

• Revenue grew 20% year-over-year to $107.5M.
• ARR reached $408M, a 23% increase.

DXC Technology reported total revenue of $3.17 billion for Q4 FY25, a decrease of 6.4% year-over-year. Diluted earnings per share was $1.43, a significant improvement from a loss in the prior year quarter. Non-GAAP diluted earnings per share was $0.84, down 13.4% year-over-year. The company achieved a book-to-bill ratio of 1.22x.

• Total revenue for Q4 FY25 was $3.17 billion, down 6.4% year-over-year.
• Diluted earnings per share for Q4 FY25 was $1.43, compared to ($1.10) in the prior year quarter.

New Fortress Energy experienced a sharp decline in revenue and recorded a net loss during Q1 2025. However, the company completed a major asset sale in Jamaica to reduce debt and improve its financial structure.

• Reported a net loss of $197 million for Q1 2025.
• Revenue fell to $470.5 million compared to $690.3 million in Q1 2024.

dLocal had a strong Q1 2025, with revenue reaching $216.8M and net income more than doubling YoY. The company saw a sharp rise in TPV and maintained robust profitability across operations.

• Revenue hit a record $216.8M, up from $184.4M in Q1 2024.
• Net income rose to $46.7M, driven by operational efficiency and favorable FX movements.

In Q4 2025, Hawkins delivered its strongest quarterly results to date, led by a 21% surge in Water Treatment revenue. Gross profit rose 15% YoY, while EPS and adjusted EBITDA increased by 18% each. All business segments contributed to the revenue growth.

• Q4 revenue rose 10% YoY to a record $245.3M.
• Water Treatment segment led growth with a 21% YoY increase.

Iris Energy posted $148.1 million in revenue in Q3 FY25, with substantial contributions from Bitcoin mining and a 33% increase in AI cloud services. The company reported $24.2 million in net income and continued scaling its AI infrastructure while pausing mining expansion at 50 EH/s.

• Achieved record revenue of $148.1 million, up from $119.6 million in Q2.
• Bitcoin mining revenue rose to $141.2 million, with 1,514 BTC mined.

Fidelis Insurance Group posted a $42,500,000 net loss in Q1 2025, primarily due to $333,300,000 in catastrophe and large losses, including impacts from California wildfires. Despite these setbacks, the company achieved strong top-line growth of nearly 14% and saw improvement in investment income.

• Fidelis posted a $42,500,000 net loss due to elevated catastrophe and large losses.
• Gross premiums written rose 13.8% YoY to $1,722,900,000.

Star Bulk maintained profitability with a $0.5M net income despite a significant decline in revenue and charter rates due to seasonal and market headwinds. The company upheld capital returns through dividends and share buybacks while continuing to deleverage and optimize its fleet.

• Maintained profitability with $0.5M net income despite a weak market.
• TCE rate fell to $12,439/day, reflecting seasonal softness and lower charter rates.

The company maintained steady revenue in U.S. dollars despite FX headwinds, with strong growth in digital engagement and loyalty members. Profitability declined year-over-year due to margin pressures, particularly in Brazil, although SLAD showed notable recovery.

• Revenue was flat YoY at $1.1 billion, but up 14.1% in constant currency.
• Adjusted EBITDA dropped to $91.3 million from $108.9 million in Q1 2024.

SFL Corporation Ltd. reported a net loss of $31.9 million, or $0.24 per share, in Q1 2025, primarily due to impairments on older dry bulk vessels. The company received $193.5 million in charter hire and reported Adjusted EBITDA of $108.0 million from consolidated subsidiaries, alongside continued fleet renewal and share repurchases.

• Reported a net loss of $31.9 million for the first quarter.
• Received $193.5 million in total charter hire during the quarter.

Endava reported a 11.7% year-over-year revenue increase to £194.8 million in Q3 FY2025. Diluted EPS improved to £0.18 from a loss in the prior year, and Adjusted Diluted EPS rose to £0.34. The company noted challenges in converting pipeline into revenue due to client hesitations in signing larger contracts.

• Revenue for Q3 FY2025 increased by 11.7% year-over-year to £194.8 million.
• Diluted EPS was £0.18 for the quarter, a significant improvement from the prior year loss.

Kornit Digital delivered Q1 2025 results showing year-over-year revenue growth and improved margins. While the company posted a GAAP net loss, it achieved a non-GAAP net income and continued to generate positive cash flow from operations.

• Revenue reached $46.5 million, up from $43.8 million last year.
• GAAP net loss narrowed to $5.1 million from $13.2 million.

Capital Southwest generated $28,500,000 in pre-tax net investment income for Q4 2025, with adjusted NII reaching $31,300,000 after excluding one-time expenses. The company saw continued origination strength and maintained a healthy NAV per share of $16.70, despite experiencing net depreciation across its credit portfolio.

• Pre-tax net investment income was $28,500,000 or $0.56 per share.
• Adjusted pre-tax net investment income was $31,300,000 or $0.61 per share.

Nexxen delivered a solid quarter marked by record CTV and programmatic revenue, a nearly doubled Adjusted EBITDA, and a return to net profitability. The launch of nexAI and new client additions signaled strong future potential despite broader market softness.

• Achieved record Q1 programmatic revenue of $71.8M and CTV revenue of $26.4M
• Adjusted EBITDA rose 95% YoY to $23.1M, reflecting operational efficiency

Navigator Gas reported a strong first quarter in 2025, with significant increases in total operating revenues, net income, and earnings per share compared to the same period last year. The company saw improved fleet utilization and average daily time charter equivalent rates, while also completing the acquisition of three vessels and addressing a going concern issue through a new financing facility.

• Total operating revenues increased by 12.9% to $151.4 million in Q1 2025 compared to $134.2 million in Q1 2024.
• Net income attributable to stockholders rose by 19.8% to $27.0 million in Q1 2025, up from $22.6 million in Q1 2024.

Myt Netherlands (LuxExperience B.V.) reported €242.5M in revenue for Q3 FY25 with solid year-over-year growth and a gross profit margin of 44.8%. While the company posted a net loss of €5.5M, it maintained positive adjusted EBITDA and strengthened profitability metrics, reaffirming guidance amidst macroeconomic headwinds.

• Net sales increased 3.8% year-over-year to €242.5M
• Adjusted EBITDA improved to €9.3M with a margin of 3.9%

Jack in the Box Inc. reported a net loss of $142.2 million in the second quarter of fiscal 2025, a significant decrease from net earnings of $25.0 million in the prior year quarter, primarily due to a non-cash goodwill and intangible impairment charge for Del Taco. Total revenues decreased by 7.8% to $336.7 million.

• Diluted loss per share was ($7.47), compared to diluted earnings per share of $1.26 in the prior year quarter.
• Operating Earnings Per Share, a non-GAAP measure, was $1.20, down from $1.46 in the prior year quarter.

Riskified expanded vertically and geographically in Q1 2025, achieving 8% revenue growth and a 2% adjusted EBITDA margin. The company posted a net loss but maintained a strong cash position and positive free cash flow.

• Revenue increased 8% year-over-year to $82.4 million
• Achieved $1.3 million in adjusted EBITDA, reflecting operational efficiency

Okeanis Eco Tankers generated $80,147,652 in revenue and $12,555,933 in net income during Q1 2025, reflecting weaker market conditions and lower TCE rates across its VLCC and Suezmax fleet. Despite the revenue drop, the company maintained efficient operations and declared a $0.32 per share dividend.

• Revenue declined to $80,147,652 due to a sharp drop in TCE rates.
• Net income was $12,555,933, down from $41,555,603 a year earlier.

Crescent Capital BDC posted $42,129,000 in revenue and $16,621,000 in net income for Q1 2025. The decline in revenue was driven by lower interest and dividend income, while unrealized and realized losses weighed on total performance. NAV per share decreased to $19.62, reflecting negative valuation adjustments across the portfolio.

• Investment income totaled $42,129,000 for Q1 2025, down from the prior quarter.
• Net income was $16,621,000 or $0.45 per share.

TMC the metals company Inc. incurred a net loss of $20,588,000 or $0.06 per share for Q1 2025. Cash used in operations totaled $9,347,000 and the company ended the quarter with $2,346,000 in cash. The reported loss reflects ongoing exploration, share-based compensation, and general administrative expenses.

• Net loss for Q1 2025 was $20,588,000 or $0.06 per share.
• Operating loss totaled $18,015,000 driven by exploration and administrative expenses.

Boston Omaha Corporation reported total revenues of $27.7 million for the first quarter of 2025, an increase from the prior year. The company experienced a net loss attributable to common stockholders of $0.7 million, a significant improvement compared to the $2.8 million loss in the same period last year. Key segments like Billboard Rentals, Broadband Services, and Premiums Earned all showed revenue growth.

• Total revenues increased to $27.7 million in Q1 2025 from $25.6 million in Q1 2024.
• Net loss attributable to common stockholders improved significantly to $0.7 million in Q1 2025 from $2.8 million in Q1 2024.

Codexis posted $7.5 million in revenue for Q1 2025, a sharp decline from the prior year due to absence of one-time licensing income. The company reported a net loss of $20.7 million, citing higher R&D expenses and a delay in a $2.5 million customer order. Despite the setback, Codexis emphasized strategic progress with its ECO Synthesis™ platform and maintained its 2025 revenue guidance.

• Revenue declined to $7.5 million from $17.1 million in Q1 2024 due to prior year one-time revenue events.
• Net loss increased to $20.7 million, or $0.25 per share.

Bitfarms posted a $36 million net loss in Q1 2025, despite achieving $67 million in revenue and strong hashrate and efficiency improvements. The company continued its strategic pivot to high-performance computing and secured major financing for U.S.-based data center development.

• Revenue rose to $67 million, up 33% year-over-year.
• Hashrate surged 200% to 19.5 EHuM, with improved mining efficiency.

Nyxoah recorded €1.1 million in revenue for Q1 2025, slightly below last year. The company's operating loss widened to €20.6 million as it ramped up expenses in preparation for the U.S. commercialization of its Genio® system. With the FDA approval process nearing completion, Nyxoah maintained a strong cash position to support its strategic objectives.

• Revenue reached €1.1 million, a slight decline from Q1 2024.
• Operating loss increased to €20.6 million due to commercialization and R&D expenses.

Celcuity posted a net loss of $37.0 million for Q1 2025, primarily driven by a significant increase in research and development expenses related to its Phase 3 trials. Despite no reported revenue, the company maintained a strong cash position of over $205 million, sufficient to fund clinical programs through 2026. The company expects multiple data readouts from its ongoing studies later this year.

• Net loss increased to $37.0 million compared to $21.6 million in Q1 2024.
• Research and development expenses rose to $32.2 million, up from $20.6 million.

In Q4 2025, Park Aerospace achieved $15.3 million in net sales and $2.6 million in net income, marking improvements over the previous year’s quarter. Operating income and margins also improved as the company continues to benefit from increased aerospace demand and operational efficiencies.

• Net sales reached $15.3 million, up from $12.6 million in Q4 2024.
• Net income was $2.6 million, up from $1.7 million in the same period last year.

Spire Global generated $23.9 million in revenue in Q1 2025 but reported a net loss of $20.7 million, reflecting higher operating expenses including a loss on decommissioned satellites. Despite the loss, the company improved operating cash flow by 5% year-over-year and eliminated all debt in April, ending the quarter with $136 million in liquidity. Spire remains focused on expanding its government contracts and AI-powered weather modeling capabilities.

• Revenue for Q1 2025 was $23.9 million, with 57% from the Americas.
• Net loss was $20.7 million, or $0.77 per share.

Innoviz achieved record revenues of $17.4 million in Q1 2025, reflecting strong growth driven by LiDAR shipments and NRE services, while net loss narrowed significantly year-over-year.

• Revenue more than doubled year-over-year to $17.4 million.
• Net loss decreased to $12.6 million from $30.1 million a year ago.

Luminar's Q1 2025 revenue declined to $18.9 million, reflecting reduced contributions from non-series production customers, partially offset by increased series production and NRE revenue. The company reported a GAAP net loss of $76.5 million and a Non-GAAP net loss of $63.1 million. It shipped approximately 6,000 LiDAR units during the quarter, marking a 50% sequential increase, and improved its free cash flow position.

• Revenue fell 16% QoQ and 10% YoY to $18.9M, aligned with guidance.
• Net loss narrowed to $76.5M from $125.7M YoY; Non-GAAP net loss was $63.1M.

European Wax Center saw a slight revenue decline but achieved growth in adjusted net income and adjusted EBITDA. The company also reiterated its full-year outlook and continued executing on strategic priorities including marketing and franchisee support.

• Revenue declined slightly to $51,427,000 compared to $51,874,000 last year.
• GAAP Net Income dropped to $2,570,000, down 29.7% year-over-year.

eGain delivered a modest GAAP net income of $66,000 on $21 million in revenue for Q3 2025, with SaaS revenue declining 4% and professional services down 29% year-over-year. Despite revenue softness, the company achieved $2.2 million in operating cash flow and $765,000 in non-GAAP net income, maintaining a strong cash position.

• Total revenue was $21.0 million, down 6% YoY.
• GAAP net income was $66,000, or $0.00 per share.

CSP Inc. reported a decrease in revenue and net income for the fiscal second quarter ended March 31, 2025, compared to the prior year period. The decline was primarily attributed to a multi-million dollar agreement in the prior year. Despite the decrease, the company highlighted continued momentum for its AZT PROTECT product and maintained a strong cash position.

• Revenue for the fiscal second quarter decreased to $13.1 million from $13.7 million in the prior year.
• The company reported a net loss of $0.1 million, or $(0.01) per diluted common share.

In Q1 2025, scPharmaceuticals achieved $11.8 million in FUROSCIX revenue, a 93% increase from the same period last year. The company filled 13,900 doses and added over 4,200 unique prescribers. While operating expenses grew due to R&D and commercialization, the company maintained a cash balance of $57.5 million.

• Generated $11.8 million in FUROSCIX revenue, up 93% YoY.
• Filled approximately 13,900 doses in Q1 2025, a 73% increase YoY.

Zentalis Pharmaceuticals reported a net loss of $48.3 million for the first quarter of 2025, a significant decrease from the net income of $10.1 million in the same period last year, primarily due to the absence of license revenue and higher operating expenses including restructuring costs. The company ended the quarter with $332.5 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into late 2027. Key operational progress included the first patient dosed in Part 2a of the Phase 2 DENALI clinical trial for azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer.

• Net loss for Q1 2025 was $48.3 million, compared to net income of $10.1 million in Q1 2024.
• Cash, cash equivalents, and marketable securities totaled $332.5 million as of March 31, 2025, providing an operational runway into late 2027.

Journey Medical generated $13.1 million in net revenue for Q1 2025, supported by a $2.1 million contribution from the commercial launch of Emrosi. Despite flat revenue year-over-year, the company improved its gross margin to 64% and reduced its overall net loss. Operating expenses were driven by Emrosi-related sales activity, with no R&D spending in the quarter.

• Total revenue was $13.1 million, nearly flat YoY but included $2.1 million from Emrosi’s launch.
• Gross margin improved to 64%, up from 54% in Q1 2024.

The Oncology Institute generated $104.4 million in revenue in Q1 2025, driven by strong performance in its dispensary segment and moderate growth in patient services. The company narrowed its net loss to $19.6 million, achieved a 44.1% increase in gross profit, and significantly improved its adjusted EBITDA. Strategic capitation contracts added over 100,000 covered lives and supported guidance reaffirmation.

• Revenue rose 10.3% YoY to $104.4 million, with strong growth in the dispensary segment.
• Gross profit increased 44.1% to $17.2 million, aided by contract rebates and higher margins.

GCT Semiconductor posted $0.5 million in revenue for Q1 2025, down 84.8% year-over-year, with a gross margin of 17.7%. The company reported a net loss of $7.0 million and continued to invest in R&D and operational alignment ahead of its 5G chipset launch, which is expected to begin sampling in late May 2025.

• Revenue fell to $0.5 million, an 84.8% decline from Q1 2024.
• Gross margin was 17.7%, down from 59.8% YoY.

Rekor Systems experienced a 6% decline in revenue year-over-year for Q1 2025, while significantly narrowing its Adjusted EBITDA loss and reducing operating expenses, highlighting improvements in cost management and efficiency.

• Revenue for Q1 2025 decreased by 6% to $9.2 million due to weather and project slowdowns.
• Net loss was reduced to $10.87 million from $18.61 million in Q1 2024.

Fossil Group reported Q1 2025 revenue of $233.3 million, down 8.5% year-over-year, but achieved significant improvements in gross margin and reduced net loss through restructuring and cost efficiencies.

• Revenue fell 8.5% year-over-year to $233.3 million, impacted by smartwatch decline and store rationalization.
• Gross margin expanded 890 basis points to 61.3%, driven by favorable mix and reduced freight costs.

Adverum Biotechnologies reported a net loss of $47.0 million for the first quarter of 2025, an increase from the $27.1 million loss in the same period last year. Research and development expenses significantly increased to $28.7 million due to activities related to the Phase 3 clinical trial, while general and administrative expenses also rose to $19.5 million.

• Net loss for Q1 2025 was $47.0 million, compared to $27.1 million for Q1 2024.
• Research and development expenses increased to $28.7 million in Q1 2025 from $15.4 million in Q1 2024, driven by Phase 3 clinical trial activities.

PDS Biotechnology reported a net loss of $8.5 million for the first quarter of 2025, an improvement from the $10.6 million net loss in the same period last year, primarily due to increased benefit from income taxes and lower operating expenses. The company also highlighted progress in its clinical trials, including the initiation of the VERSATILE-003 Phase 3 trial and FDA clearance for a new IND application.

• Net loss for Q1 2025 was approximately $8.5 million, an improvement from $10.6 million in Q1 2024.
• Research and development expenses decreased to $5.8 million in Q1 2025 from $6.7 million in Q1 2024.

Xos, Inc. delivered 29 units and generated $5.9 million in revenue in Q1 2025, marking a decrease from the prior year. However, it reported positive GAAP gross profit and a 19.6% reduction in operating expenses, highlighting operational improvements despite macroeconomic challenges.

• Delivered 29 units and generated $5.9 million in revenue, down from 62 units and $13.2 million in Q1 2024.
• Gross profit reached $1.2 million, a turnaround from a loss in Q4 2024.

Allurion reported its first quarter 2025 financial results, showing reduced operating expenses and net operating loss, an improved gross margin, and progress toward FDA approval, while maintaining its full-year revenue guidance.

• Reported first quarter 2025 revenue of $5.6 million.
• Achieved a gross margin of 75% in Q1 2025, compared to 73% in the prior year.

Palatin Technologies reported no revenue for the fiscal third quarter ended March 31, 2025, following the sale of Vyleesi rights. The company significantly reduced its net loss and operating expenses compared to the same period last year, primarily due to decreased spending on MCR programs. They ended the quarter with $2.5 million in cash and cash equivalents and are exploring funding options.

• No product revenue was recorded in the quarter due to the sale of Vyleesi's worldwide rights.
• Total operating expenses decreased significantly to $4.8 million from $9.2 million in the prior year.

Moleculin Biotech reported a net loss of $6.4 million in Q1 2025 with no revenue, while continuing progress on its Annamycin trials for AML and STS lung metastases. Research and development expenses decreased year-over-year, and the company held $7.7 million in cash and equivalents as of quarter end.

• No revenue was reported for Q1 2025.
• Net loss totaled $6.4 million compared to $5.0 million in Q1 2024.

Equillium, Inc. experienced a significant net loss of $8.654 million in the first quarter of 2025, with no revenue generated during this period. The company's operating expenses decreased, primarily due to a wind-down of clinical studies and CMC activities. The company's cash and cash equivalents stood at $14.502 million as of March 31, 2025, and management believes these funds will be sufficient to fund operations into the third quarter of 2025.

• Net loss for Q1 2025 was $8.654 million, a significant increase from $2.734 million in Q1 2024.
• No revenue was recognized in Q1 2025, compared to $10.689 million in Q1 2024, due to the termination of the Asset Purchase Agreement with Ono.

BioNano Genomics delivered Q1 2025 revenue of $6.5 million, down 26% year-over-year, primarily due to reduced instrument and discontinued clinical services sales. Despite this, the company improved its gross margin to 46% and significantly reduced its operating expenses, resulting in a narrowed net loss.

• Revenue declined to $6.5 million from $8.8 million in Q1 2024, driven by discontinued services and lower instrument sales.
• Gross margin improved to 46%, up from 32% in the prior year quarter.

Aytu BioPharma achieved 32% revenue growth year-over-year in Q3 2025, driven by robust performance in both its ADHD and Pediatric portfolios. The company reported net income of $4.0 million and adjusted EBITDA of $3.9 million, reflecting successful execution of its strategic realignment and cost optimization efforts.

• Total revenue grew 32% year-over-year to $18.5 million.
• Net income reached $4.0 million, compared to a $2.9 million loss in the prior year period.

Talphera reported $27,000 in revenue and a net loss of $2.6 million in Q1 2025, reflecting lower operating expenses compared to the prior year. The company made progress on its NEPHRO CRRT trial and secured the first tranche of a $14.8 million financing to support clinical development.

• Revenue for Q1 2025 was $27,000 compared to zero in Q1 2024.
• Net loss narrowed to $2.6 million from $4.0 million a year ago.

Precipio delivered a 43% YoY revenue increase in Q1 2025, driven by gains in both its Products and Pathology Services divisions. Gross margins improved substantially, and adjusted EBITDA showed significant progress toward profitability, reflecting better cost control and operational efficiency.

• Revenue reached $4,900,000, up 43% YoY despite a seasonal dip from Q4.
• Gross margin rose to 43%, driven by improvements across both divisions.